Cost-effectiveness of PCSK9 Inhibitors for Heterozygous FH or ASCVD | Cardiology | Learning | The JAMA Network
[Skip to Content]
Sign In
Individual Sign In
Create an Account
Institutional Sign In
OpenAthens Shibboleth
Purchase Options:
[Skip to Content Landing]
Sign in or Create an Account to track your personal CME/MOC activities
0 Credit Video 3 min 41 sec JAMA August 16, 2016

Cost-effectiveness of PCSK9 Inhibitors for Heterozygous FH or ASCVD

×